)
Hyderabad-based bio-pharmaceutical company Suven Life Sciences Limited has secured one product patent each from South Korea, China and Canada corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.
These patents are valid through 2029 and 2031.
The granted patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents. They are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and schizophrenia.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally", Suven chief executive officer, Venkat Jasti, said in a statement.
With these new patents, Suven has a total of 14 granted patents each from South Korea and China and 16 patents from Canada.
The company stated that the patents are its exclusive intellectual property and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
